By Lisa Kerner
Erie, Pa., May 22 - Naryx Pharma, Inc. said it completed an $8 million round of series B2 financing.
Proceeds will be used to advance the development of the company's lead products.
Vivo Ventures led the financing round with participation from Sutter Hill Ventures.
Chen Yu and Ed Engleman, both of Vivo Ventures, will join the Naryx board of directors.
Located in Santa Barbara, Calif., Naryx is a biopharmaceutical company that develops products for the treatment of chronic sinusitis.
| Issuer: | Naryx Pharma, Inc.
|
| Issue: | Series B2 financing
|
| Amount: | $8 million
|
| Investors: | Vivo Ventures (lead), Sutter Hill Ventures
|
| Announcement date: | May 22
|
|
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
